TABLE 3.
Sensitivity and specificity of different NS1 IgG ELISAsa
| Panelb | DENV1 NS1 ELISA |
DENV2 NS1 ELISA |
DENV3 NS1 ELISA |
DENV1-4 NS1 ELISA |
ZIKV NS1 ELISA |
|||||
|---|---|---|---|---|---|---|---|---|---|---|
| % Sens (95% CI) | % Spec (95% CI) | % Sens (95% CI) | % Spec (95% CI) | % Sens (95% CI) | % Spec (95% CI) | % Sens (95% CI) | % Spec (95% CI) | % Sens (95% CI) | % Spec (95% CI) | |
| Overall | 94.5 (89.8–96.9) | 91.9 (87.1–94.4) | 78.9 (67.8–84.5) | 87.3 (81.3–90.4) | 61.5 (48.3–68.3) | 92.7 (87.8–95.2) | 95.6 (91.4–97.8) | 89.5 (84.1–92.3) | 100 (67.8–84.5) | 82.9 (77.3–85.7) |
| pDENV1 | 100 (100–100) | NAc | 47.6 (26.3–58.5) | NA | 23.8 (5.6–33.1) | NA | 95.2 (86.1–99.9) | NA | NA | 100 (100–100) |
| pDENV2d | 71.4 (38.0–88.5) | NA | 100 (100–100) | NA | 42.9 (6.2–61.6) | NA | 100 (100–100) | NA | NA | 100 (100–100) |
| pDENV3 | 100 (100–100) | NA | 75 (32.6–96.7) | NA | 100 (100–100) | NA | 100 (100–100) | NA | NA | 100 (100–100) |
| sDENV | 94.9 (89.3–97.8) | NA | 100 (100–100) | NA | 100 (100–100) | NA | 94.9 (89.3–97.8) | NA | NA | 49.2 (36.4–55.7) |
| Naive | NA | 98.2 (94.7–100) | NA | 98.0 94.0–100) | NA | 100 (100–100) | NA | 100 (100–100) | NA | 100 (100–100) |
| pWNV | NA | 100 (100–100) | NA | 97.2 (91.9–100) | NA | 100 (100–100) | NA | 97.2 (91.9–100) | NA | 100 (100–100) |
| pZIKVd | NA | 100 (100–100) | NA | 94.4 (83.9–99.8) | NA | 100 (100–100) | NA | 100 (100–100) | 100 (100–100) | NA |
| ZIKVwprDENVd | NA | 40 (15.2–52.7) | NA | 20 (0–30.3) | NA | 46.7 (21.4–59.6) | NA | 20 (0–30.3) | 100 (100–100) | NA |
a
ELISAs, enzyme-linked immunosorbent assays; Sens, sensitivity; Spec, specificity; CI, confidence interval. For those with repeated samples, only one sample from each subject was included.
b
pDENV1, primary DENV1 infection; pDENV2, primary DENV2 infection; pDENV3, primary DENV3 infection; pWNV, primary WNV infection; pZIKV, primary ZIKV infection; sDENV, secondary DENV infection; ZIKVwprDENV, ZIKV infection with previous DENV infection.
c
NA, not applicable.
d
Samples at postconvalescent phase (≥3 months post-symptom onset) are presented.